Antagonists or blocking antibodies against CSF1R suppress the accumulation of TAMs as well as changing their phenotype, enhance CD8+ T cell-mediated antitumor immune responses, and prevent disease progression or primary tumor growth in mouse models of glioblastoma, pancreatic, colon, and breast cancer (13–16). Here, CD8A is linked to breast cancer.